NCT02568553 2025-11-26Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1 Completed35 enrolled
NCT02961881 2024-02-02A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaAmgenPhase 1 Completed35 enrolled 27 charts
NCT00274742 2015-01-16Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHLAmgen Research (Munich) GmbHPhase 1 Completed76 enrolled 15 charts
NCT00538096 2008-09-05A Phase I Study to Evaluate Safety, Tolerability in Adults With LymphomaMedImmune LLCPhase 1 Withdrawn18 enrolled